The Ontario Neurodegenerative Disease Research Initiative

Introduction

With heterogeneous symptoms that interfere with daily functioning, including cognitive impairment and/or the deterioration of motor abilities, neurodegenerative diseases take a substantial toll on the quality of life for patients and their families, and results in a myriad of burdens across social, economic, and healthcare systems¹.

Several large studies examine specific neurodegenerative diseases^2–5. These include cohort studies such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Parkinson Progression Marker Initiative (PPMI), which have advanced our understanding of prototypical Alzheimer’s disease (AD) and Parkinson’s disease (PD), respectively. However, there is growing awareness that pathological mechanisms may overlap among neurodegenerative diseases^6-9, especially in relation to the development of cognitive and motor decline. Furthermore, neurodegeneration can be exacerbated by cerebrovascular disease (CVD)¹⁰. The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a longitudinal, multi-site, observational cohort study undertaken to enable the exploration and extend our knowledge of similarities and differences within and among neurodegenerative conditions, their relationship with cerebrovascular disease, and potential synergistic mechanisms yielding cognitive and motor decline¹¹. Participants were recruited into five disease cohorts: (1) AD and amnestic mild cognitive impairment (MCI), (2) amyotrophic lateral sclerosis (ALS), (3) frontotemporal dementia spectrum disorders (FTD), (4) PD, and (5) CVD, and were assessed annually with a rigorous set of measurement tasks across seven diverse assessment platforms. Herein, we describe the recruitment and characteristics of the ONDRI cohort at baseline allowing for more nuanced analyses of these data and appropriate interpretation of subsequent publications.

Methods

Eligibility and recruitment

Participants were recruited through tertiary clinics at fourteen academic health science centres in six cities across Ontario, Canada. Figure 1 lists general and platform-specific inclusion and exclusion criteria; additional details are elsewhere¹¹. Eligible participants were previously diagnosed with one of the ONDRI-focused diseases and met consensus diagnostic criteria that was contemporary at the time of enrolment: AD¹², including both amnestic and non-amnestic presentations; MCI with single- or multi-domain amnestic involvement¹³; possible, probable, or definite ALS, based on revised El Escorial criteria¹⁴; FTD spectrum disorders, including behavioural variant FTD¹⁵, corticobasal syndrome¹⁶, progressive supranuclear palsy¹⁷, and progressive primary aphasia, including agrammatic/non-fluent and semantic variants¹⁸ but not the logopenic variant; idiopathic PD with or without cognitive impairment¹⁹; or CVD with or without cognitive impairment. Participants eligible for the CVD cohort experienced a mild to moderate ischemic stroke/transient ischemic attack (TIA) (individuals with large cortical strokes were excluded) confirmed by clinical imaging (CT and/or MRI at least three months prior to enrolment.

• Download figure
• Open in new tab

Figure 1: General and platform-specific inclusion and exclusion criteria

Any changes from the previous publication¹¹ are underlined. LEAP-Q = Language Experience and Proficiency Questionnaire; MoCA = Montreal Cognitive Assessment; AD = Alzheimer’s disease; FTD = frontotemporal dementia spectrum disorder; ALS= amyotrophic lateral sclerosis.

MRI scans, collected according to a standardized Canadian protocol²⁰ as part of the neuroimaging assessment, for all participants recruited to the AD/MCI cohort were assessed before enrolment by a research neuroradiologist to confirm absence of significant pathology that suggested a non-Alzheimer’s related cause of cognitive impairment²¹.

The study aimed to enrol individuals with clinical characteristics that would maximize the ability to observe disease progression and permit the identification of differences and/or similarities between the various trajectories of aging with neurodegenerative disease, especially with respect to cognition. As a result, disease-specific inclusion criteria targeted individuals in the earlier stages of disease, and clinicians recruiting for the CVD or PD cohorts were encouraged to enrol both cognitively intact participants and participants with some evidence of cognitive impairment/dementia, as defined by a cut-off of 26 on the Montreal Cognitive Assessment (MoCA)²². Further, clinicians recruiting to the PD cohort were encouraged to enrol more participants 65 years of age or older (a proportion of two-thirds) than those younger than 65 years as changes in cognition were more likely to be observed in an older population.

A healthy control cohort with overlapping assessments to ONDRI has also been collected from the Brain-Eye Amyloid Memory study²³. Baseline characteristics of this control cohort will be reported in a separate paper.

Results

Recruitment

Participants were recruited between July 2014 and March 2017. Some inclusion and exclusion criteria were amended during the course of the study resulting in a broadening of the field of eligible participants.

In total, 630 individuals provided written informed consent to participate in ONDRI and were screened. Ultimately, 25 (4%) withdrew consent during screening and 94 (18%) did not meet inclusion criteria (Figure 2). However, 9 (1%) met inclusion criteria for a different cohort and were subsequently enrolled there.

• Download figure
• Open in new tab

Figure 2: Consort diagram for individuals recruited to ONDRI

AD/MCI = Alzheimer’s disease and amnestic mild cognitive impairment; ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia spectrum disorder; PD = Parkinson’s disease; CVD = cerebrovascular disease.

^aParticipant originally recruited to FTD cohort

^bParticipants originally recruited to AD/MCI cohort

Table 1 summarizes the inclusion criteria not met by 94 of the recruited individuals. Nine individuals were excluded from the disease cohort to which they were recruited based on MRI results challenging disease-specific requirements: 8 participants were excluded from the AD/MCI cohort (2 with Alzheimer’s disease and 6 with mild cognitive impairment) due to sufficient vascular pathology was identified, motivating their transfer to the CVD cohort²¹; and 1 participant was transferred from the FTD cohort (behavioural variant) to the AD/MCI cohort after prominent hippocampal atrophy instead of frontotemporal involvement was identified, with further historical clarification showing evidence of memory decline as the presenting symptom, in addition to behavioural dysregulation.

View this table:

• View inline
• View popup
• Download powerpoint

Table 1: Number (proportion) of individuals that did not meet inclusion criteria for criterion

MoCA = Montreal Cognitive Assessment; AD/MCI = Alzheimer’s disease and amnestic mild cognitive impairment; ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia spectrum disorder; PD = Parkinson’s disease; CVD = cerebrovascular disease.

Multivariate relationships between demographic, study partner, and MoCA variables

In order to understand dependencies among clinical and demographic variables, which is required for modelling their role as factors in cognitive and motor impairments, we identified multivariate associations using MCA.

Two components explained 25.8% of the total variance (17.2% and 8.7% separately). As illustrated in Figure 3(A), Component 1 indicates that participants who are not married, have non-spousal study partners (i.e., friends, adult children, and other relatives), and do not live with their study partner are associated. Component 2 shows that male participants, female study partners, younger participants, younger study partners, higher MoCA total scores, and higher education are associated. Black, south Asian, and other ethnicities are associated with both components.

• Download figure
• Open in new tab

Figure 3: Component maps of Multiple Component Analysis results

A) Variable component scores; B) Participant component scores. Response categories with fewer observed responses have been combined: For education, ‘HS.or.less’ includes participants with less than a high school education, as well as those who earned their diploma; ‘Master..Professional’ includes participants in any of the ‘Master’s degree’, ‘Doctoral degree’, or ‘Professional school’ response categories. For ethnicity, ‘Other’ includes response categories ‘don’t know’ or ‘prefer not to answer.’ For marital status, ‘Not.Married’ includes participants who were separated, divorced, widowed, or never married. MoCA = Montreal Cognitive Assessment total score; SP = study partner; HS = high school; AD/MCI = Alzheimer’s disease and amnestic mild cognitive impairment; ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia spectrum disorder; PD = Parkinson’s disease; CVD = cerebrovascular disease.

Reflecting these associations, participants clustered into three groups, as illustrated in Figure 3(B). The right hand cluster included 127 participants (24%) who were not married, had a non- spousal study partner, or did not live with their study partner. Most of this group was female (67%) and 24% were of black, south Asian, or other ethnicity. Of the remaining 393 participants (76% of all 520), 386 (98%) were married, had a spousal study partner, and lived with their study partner; 46 (12%) were of black, south Asian, or other ethnicity. The upper left cluster included 89 participants (17% of all 520) of whom 86 (97%) were female and 33 (37%) had attained a Bachelor’s degree or higher, while the lower left cluster included 304 participants (58% of all 520) of whom 3 (1%) were female and 159 (52%) had attained a Bachelor’s degree or higher.

Discussion

ONDRI collected a wide array of data across multiple assessment platforms with which researchers can study clinical and biological features within, between, and across multiple common neurodegenerative diseases associated with aging and cerebrovascular disease. The distribution of age, sex, education, and ethnicity are similar to other studies of specific neurodegenerative diseases^2-5.

The MCA highlighted that requiring a study partner may have influenced sample demographic characteristics. Consistent with other studies including a study partner⁴⁰, a majority of ONDRI participants had a spousal study partner. Work obligations and logistical challenges (e.g., not living with the participant) often interfere with the ability of other relatives or friends to participate⁴⁰. Participants with spousal study partners are more often male, white, and more educated⁴⁰, as was reflected in our sample. Further, previous research has shown that individuals who identify as non-white are more likely to support non-spousal family members or friends⁴⁰. The MCA also identified associations between age, education, and MoCA total score. Consistent with previous research on the MoCA⁴¹, participants with higher MoCA scores were generally younger and had attained higher levels of education. Studies of cognition must consider the inter- play between assessment measures and potentially influential demographic characteristics in order to draw appropriately nuanced conclusions regarding impairment, preservation, or decline. Some disease cohorts were recruited more heavily from particular geographic regions of Ontario. For example, ALS participants were more heavily recruited from Hamilton, a city known for its large share of the manufacturing industry, than other regions. A higher proportion of technical degrees in this cohort may be attributed to this recruitment decision and, importantly, level of education and occupational attainment may influence performance on cognitive assessments⁴². As a result, differences between cohorts may also be partially attributable to recruitment patterns across regions with different demographic distributions.

ONDRI enrolled participants across a range of disease severities, though participants in earlier stages of disease, with features that suggest an increased likelihood of participation in comprehensive follow-up, predominate each cohort. Specifically, in addition to the MCI subgroup, more than half of participants in the AD subgroup had reportedly intact basic activities of daily living and relatively mild deficiencies noted on instrumental activities of daily living, showing early stages of impairment in this cohort. The majority of ALS participants were diagnosed with limb onset ALS and therefore had better prognosis than those with bulbar onset, depending on other factors such as age⁴³. The majority of FTD participants had no more than slight symptoms on non-motor experiences of daily living. Over half of participants in the PD cohort had no more than slight symptoms on most aspects of daily living, indicative of an opportunity to observe disease progression over follow-up visits⁴⁴. Nearly three-quarters of participants in the CVD cohort scored 0 or 1 on the modified Rankin scale, suggesting few symptoms or activity of daily living restrictions three or more months post-stroke, and increasing the likelihood of their participation across all data collection timepoints⁴⁵.

Heterogeneity within disease was designed in order to capture a wide spectrum of clinical presentations: (1) both typical and atypical presentations of Alzheimer’s disease, as well as amnestic mild cognitive impairment are represented in the AD/MCI cohort, (2) the FTD cohort included five disease subtypes including behavioural variant, agrammatic/non-fluent variant of primary progressive aphasia, and progressive supranuclear palsy as the most frequent, (3) the CVD and PD cohorts enrolled both cognitively intact and impaired participants. Minor variances in clinical characteristics were also induced through protocol amendments. Lastly, unintended features emerged during initial data explorations including incidental strokes observed in a few ALS, FTD, and PD participants. However, a research neuroradiologist confirmed that these incidental strokes did not interfere with disease-specific symptoms and the participants remained in the cohorts to which they were recruited.

Two approaches to this ONDRI sample that capitalize on this diversity are indicated. For analyses within disease cohorts, explicit acknowledgement of heterogeneity through investigation of subgroups could illuminate important differences within standard clinical diagnoses. Alternatively, a disease-agnostic approach that considers ONDRI participants as a sample of individuals with neurodegenerative or cerebrovascular disease by removing disease labels may identify some features that align well with baseline diagnosis, and other patterns that are more suggestive of mixed disease. Mixed disease is being recognized as the norm rather than the exception with respect to its contribution to cognitive decline in individuals over age 65 through several longitudinal studies of aging and dementia⁶.

Studies of vascular cognitive impairment often recruit from memory clinics leading to samples with cognitive impairment at baseline. However, most participants in the CVD cohort were recruited from stroke clinics and include individuals with and without memory concerns. The inclusion of eight participants recruited for the AD/MCI cohort that were subsequently enrolled into the CVD cohort upon discovery of vascular pathologies at baseline are the exception. Analysis of this cohort may reveal implications of the different routes of entry between these eight participants and those recruited through stroke clinics.

Enrollment strategies and criteria played an important role in defining the sample, most notably for the AD/MCI cohort. Disease-specific requirements and a minimum MoCA threshold together were responsible for 56% of potential participants being excluded from this cohort. We propose two possible reasons for this phenomenon.

First, ONDRI recruited individuals through clinicians at tertiary clinics. However, when memory clinic training programs were introduced in Canada, primary-care clinics began providing effective early services for individuals with straightforward cognitive impairment⁴⁶. While this approach increased capacity for care of individuals with cognitive decline, it also created a shift in patient characteristics and clinical presentation in tertiary clinics. As a result, fewer individuals with typical presentation early in the disease course are available for recruitment from tertiary clinics. While treatment for some neurodegenerative diseases such as PD remains at the tertiary level⁴⁷, future studies of Alzheimer’s disease and/or mild cognitive impairment should consider recruitment from memory clinics at the primary-care level.

Second, standard criteria for the diagnosis of Alzheimer’s disease or mild cognitive impairment remain fundamentally clinical in Canada and best practice guidelines do not require MRI⁴⁸. As a result, multiple individuals recruited to the AD/MCI cohort presented other possible causes for cognitive decline on MRI, including vascular pathologies and markers consistent with traumatic brain injury. Such findings excluded 15 participants from the ONDRI AD/MCI cohort²¹ and reinforced the importance of neuroimaging for both research studies and in order for patients to receive more appropriate care.

Apart from adapted collection for retinal imaging, more than 80% of participants completed all assessments within eight weeks. This feat, which required stamina and dedication from participants and their study partners, indicates that the protocol was manageable for individuals in early stage neurodegenerative or cerebrovascular disease. Future research using ONDRI’s longitudinal data will be able to explore whether disease progression is related to attrition and at what stage a protocol such as this becomes too burdensome. It will also facilitate the identification of contributing factors to both slow and rapid disease progressors within and across the different neurodegenerative diseases, which is an important confound to control for in future clinical trials of potential disease-modifying agents.

Some participants are missing data for an entire assessment platform, while other missing data are intermittent throughout a platform’s measures. Participants can be missing data for various reasons, however missing data as a result of cognitive, behavioural, or physical impairment are of prominent interest as these may be more frequent among participants at more advanced stages of disease. As a result, complete case analysis may be misleading as estimates of parameters of interest would tend to indicate associations relevant only to participants with better performance. Informative missing data codes are embedded in all ONDRI data sets to assist researchers in determining appropriate approaches for accommodating missing values that maintain generalizable conclusions.

ONDRI data underwent extensive cleaning and quality control pipelines to identify and correct data entry or processing errors^26–31, or document anomalies³⁴, thereby increasing the accuracy and integrity of data and consequently reducing the risk of incorrect conclusions. While such protocols can be time consuming, they serve a two-fold benefit: more accurate results due to correction of erroneously recorded data and more nuanced analyses sensitive to idiosyncrasies in the sample.

Translational neurodegenerative disease research recognizes the importance of multi-disciplinary team science, as shown through multiple prior initiatives^2–5. Large scale and broadly accessible data encourages additional analyses on curated data but also allows researchers to merge data from multiple studies, leverage a constellation of initiatives, and accelerate discovery through broader integrations of data and wider collaborations of researchers⁴⁹.

Most neurodegeneration initiatives consider a particular cohort or disease, and because independent studies deploy different measures, assessments, and methodological specifications, cross-disease comparisons between studies are limited⁵⁰. ONDRI is in a distinct position to overcome these challenges because of its breadth of neurodegenerative diseases sampled and its depth of harmonized phenotypic characterization. In addition, data from the biomarker and pathology platform are being ascertained in order to characterize participants based on their underlying proteinopathies (e.g., antemortem plasma P181-Tau, post-mortem immunohistochemical neuropathological diagnosis), degree of neurodegeneration (e.g., plasma NfL), and markers of neuroinflammation (e.g., plasma GFAP). This data will also expand on the capacity to identify individuals with pure vs. mixed contributions to cognitive and motor decline. ONDRI data from 520 participants with neurodegenerative or cerebrovascular disease broadly captured multiple components comprising the disease profile. The outcome of the executed protocol and baseline demographic and select clinical characteristics of the participants are described to promote deep investigation into many elements of clinical, pathological, and societal mechanisms. These data will be available to the scientific community through the Ontario Brain Institute later this year.

Conflicts of Interest

SHP is a consultant for Zywie Bio LLC, working on a disease modifying treatment for Parkinson’s disease. SCS is the Chief Scientific Officer of ADx, a medical diagnostics company specializing in neuroimaging of neurodegenerative disorders.